Clinical Trial Policy meeting
This article was originally published in The Gray Sheet
Executive Summary
Medicare Coverage Advisory Committee (MCAC) will address CMS' reconsideration of the Clinical Trial Policy at a public meeting Dec. 13 in Baltimore. The policy, implemented in 2000, provides coverage of routine costs for Medicare beneficiaries enrolled in "qualified" clinical studies. CMS opened a national coverage decision in July to revise the policy in light of "changes to the clinical research landscape" (1"The Gray Sheet" Aug. 21, 2006, p. 9). A proposed decision is now expected by April 10, with a final decision due in July...
You may also be interested in...
CMS Should Clarify Coverage For Device Trials, Manufacturers Say
Device manufacturers are asking for a clearer path to Medicare coverage of their clinical studies
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.